Coronary Disease, Hypertension
Conditions
Keywords
Observational, Colombia, Metpure XL
Brief summary
This is a Phase 4, observational, open study in patients who their doctor has prescribe METPURE XL (S (-)metoprolol succinate)by clinical practice. No medication was provided by the sponsor. The planned observation time is 8 weeks. The 8 weeks of observation involves an evaluation of baseline followed by information gathered from the assessment visits at week 4 and week 8.
Interventions
None listed
Sponsors
Closter Pharma
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who were prescibed with s(-)metoprolol succinate(25mg, 50mg), depending on their clinical condition and use locally approved will be eligible to participate in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of therapy in the management of cardiovascular diseases | 8 weeks | The objective is to mesure the effect of Metpure XL in cadiovascular diseases as hypertension, post MI and coronary disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate and compare the rate of compliance with treatment | 8 weeks | Evaluate the compliance with METPURE XL, to be able to identify possible reasons for noncompliance or quitting the treatment |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 8 weeks | To assess the safety pattern in Colombian subjects using s(-)metoprolol succinate |
Countries
Colombia
Contacts
Primary ContactSandra M Casiano, MD
Backup ContactHarold Mejia
Outcome results
None listed